The Europe Digital Neuro Biomarkers Market is witnessing rapid growth owing to the use of wearables, apps, and AI-based technologies by the healthcare providers and biopharmaceuticals in tracking the progression of neurological diseases through the collection of information about patients' movements, speech, and cognitive function.
As per SNS Insider, the value of the Europe Digital Neuro Biomarkers Market was recorded at USD 0.25 Billion in 2025 and is forecasted to grow up to USD 2.13 Billion by 2035, at a CAGR of around 23.80% for 2026-2035, owing to increasing prevalence of neurological disorders, expansion of digital health initiatives by the governments, and biopharmaceuticals' clinical research activities across the region. This is in line with the global market of Digital Neuro Biomarkers, valued at USD 0.90 Billion in 2025 and forecasted to grow up to USD 8.34 Billion by 2035, at a CAGR of 24.97%, driven by increasing incidences of chronic neurological diseases and adoption of remote patient monitoring.
Gain Actionable Intelligence on the Digital Neuro Biomarkers Market - Request a Sample Report
Why Europe Is the Market's Fastest-Growing Region
The European region is becoming the most vibrant in terms of the global digital neuro biomarker market, owing to the rising occurrences of neurological diseases along with the various digital health endeavors initiated by governments. Owing to the regulatory support for digital health innovations, there remains a conducive environment for the clinical application of such technologies.
Germany is the leader in terms of regional demand, accounting for an estimated 27.30% share in European revenues. It owes its success to its high presence of biopharmaceutical companies and clinical research facilities. Likewise, the United Kingdom, France, and Nordic nations exhibit a similar trend in their digital health endeavors.
Segment Trends Relevant to Europe
Wearable devices had the biggest share in the global product market in 2025, as they could help collect data on movements, gaits, and physiology of patients, which could be relevant for neurological disease surveillance continuously and passively. The fastest growing sector is mobile applications, due to the increased adoption of smartphones and use of mobile applications for cognitive assessment, which makes it easier to monitor neurological disease development at home.
Monitoring was the most used type of application, because the demand for disease tracking among patients already diagnosed with the disease remained high. The fastest-growing type of application is predictive and prognostic application, which is associated with the shift in the clinic towards identification of people who are at risk of developing the disease. Health care organizations were the largest end-users of the products; however, pharmaceutical and biotechnology companies were the fastest-growing end-user sectors.
Companies Driving Innovation in the Digital Neuro Biomarkers Space
Koneksa Health
In 2025, Koneksa Health expanded its platform of digital endpoints and sought to address pharmaceutical and biotechnology organizations that need validated digital biomarkers for clinical trials in the field of neurology. Since European biopharmaceutical companies have started incorporating digital endpoints into their clinical trials, Koneksa has been well-positioned to assist the increasing number of clinics conducting neurology trials in Europe, especially in Germany.
Altoida
Further development of the Altoida digital biomarker diagnostic technology for Alzheimer’s disease and cognitive impairment occurred in 2025, making it a significant company in the field of digital diagnostic solutions that have been acknowledged by the FDA. In light of the rising interest of European regulators and health systems in the diagnosis of neurological conditions at an early stage, the solution offered by Altoida for diagnosing cognitive impairment fits perfectly into this sphere.
NeuraLight
NeuraLight raised twenty-five million dollars for the development of digital biomarkers for neurodegenerative diseases, demonstrating ongoing investor belief in technology that can diagnose disease biomarkers faster than conventional approaches. The investment is crucial for further developing technologies that will play a significant role in Europe’s growing initiatives for early detection and predictive monitoring, which have started changing the way clinical trials are run in the continent’s largest healthcare markets.
Other established players relevant to the European market include F. Hoffmann-La Roche, Merck KGaA, and QIAGEN N.V., all of which maintain significant European operations across neurology-focused research and diagnostics.
Market Dynamics and Outlook
Increasing neurological disease cases and personalizing medicine have been among the primary structural growth factors, supplemented by demographics and investments from both government and private sources. Validation challenges and data security concerns still represent some of the major constraints, considering the need for digital biomarker companies to accumulate enough data before receiving approval while at the same time ensuring that data security measures are strong enough for constant acquisition of behavioral and physiological data.
Integration of drug companies' clinical trials represents the most important opportunity for Europe because more and more pharmaceutical companies want to use objective, continuous measures in order to measure the effectiveness of treatment for neurodegenerative diseases. Digital biomarker companies who can provide clinically validated and regulatory-approved technology are most likely to capitalize on the European digital neuro biomarkers market until 2035.
